Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma

Journal of Urology

Volumn 185, Issue 2, 2011, Pages 439-444

  Karam, Jose A ^a   Rini, Brian I ^c   Varella, Leticia ^c   Garcia, Jorge A ^c   Dreicer, Robert ^c   Choueiri, Toni K ^b   Jonasch, Eric ^a   Matin, Surena F ^a   Campbell, Steven C ^d   Wood, Christopher G ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

carcinoma, renal cell; drug therapy; kidney; neoplasm metastasis; reoperation

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; FORETINIB; GEMCITABINE; INTERLEUKIN 2; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAZOPANIB; SORAFENIB; SUNITINIB;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER RECURRENCE; CANCER SURGERY; CHYLOUS ASCITES; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; ILEUS; INFERIOR CAVA VEIN OBSTRUCTION; INTESTINE CANCER; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MEDIASTINUM METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; PARACENTESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROPERITONEAL CANCER; RETROSPECTIVE STUDY; TOTAL PARENTERAL NUTRITION; WOUND COMPLICATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEPHRECTOMY; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651314817     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.09.086     Document Type: Article

References (28)

1. A.J. Pantuck, A. Zisman, and A.S. Belldegrun The changing natural history of renal cell carcinoma J Urol 166 2001 1611
2. R.C. Flanigan Debulking nephrectomy in metastatic renal cancer Clin Cancer Res 10 2004 6335S
3. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115
4. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125
5. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271
6. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449
7. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103
8. D.D. Daliani, N.M. Tannir, and C.N. Papandreou Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma BJU Int 104 2009 456
9. S.E. Eggener, O. Yossepowitch, and S. Kundu Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma J Urol 180 2008 873
10. B. Kim, and A.C. Louie Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission Arch Surg 127 1992 1343
11. V. Krishnamurthi, A.C. Novick, and R.M. Bukowski Efficacy of multimodality therapy in advanced renal cell carcinoma Urology 51 1998 933
12. H.W. Pogrebniak, G. Haas, and W.M. Linehan Renal cell carcinoma: resection of solitary and multiple metastases Ann Thorac Surg 54 1992 33
13. A. Sella, D.A. Swanson, and J.Y. Ro Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma J Urol 149 1993 19
14. R.M. Sherry, H.I. Pass, and S.A. Rosenberg Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy Cancer 69 1992 1850
15. S. Tanguay, D.A. Swanson, and J.B. Putnam Jr Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery J Urol 156 1996 1586
16. B.I. Rini, V. Shaw, and J.E. Rosenberg Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases Clin Genitourin Cancer 5 2006 232
17. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289
18. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205
20. A.A. Thomas, B.I. Rini, and B.R. Lane Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2009 518
21. V. Margulis, S.F. Matin, and N. Tannir Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 180 2008 94
22. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076
23. C.L. Cowey, C. Amin, and R.S. Pruthi Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 2010 1502
24. A.A. Thomas, B.I. Rini, and A.J. Stephenson Surgical resection of renal cell carcinoma after targeted therapy J Urol 182 2009 881
25. B. Shuch, S.B. Riggs, and J.C. LaRochelle Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 102 2008 692
26. Y. Je, F.A. Schutz, and T.K. Choueiri Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Lancet Oncol 10 2009 967
27. T.K. Choueiri, F.A. Schutz, and Y. Je Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280
28. D. Bose, F. Meric-Bernstam, and W. Hofstetter Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care Lancet Oncol 11 2010 373